- Home
- PNF vs RNXT Comparison
PNF vs RNXT Comparison
Compare PNF & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- RNXT
- Stock Information
- Founded
- PNF 2001
- RNXT 2012
- Country
- PNF United States
- RNXT United States
- Employees
- PNF N/A
- RNXT N/A
- Industry
- PNF Finance Companies
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PNF Finance
- RNXT Health Care
- Exchange
- PNF Nasdaq
- RNXT Nasdaq
- Market Cap
- PNF 54.9M
- RNXT 44.6M
- IPO Year
- PNF N/A
- RNXT 2021
- Fundamental
- Price
- PNF $6.94
- RNXT $1.38
- Analyst Decision
- PNF
- RNXT Strong Buy
- Analyst Count
- PNF 0
- RNXT 2
- Target Price
- PNF N/A
- RNXT $7.25
- AVG Volume (30 Days)
- PNF 29.1K
- RNXT 198.3K
- Earning Date
- PNF 01-01-0001
- RNXT 08-12-2025
- Dividend Yield
- PNF 5.17%
- RNXT N/A
- EPS Growth
- PNF N/A
- RNXT N/A
- EPS
- PNF N/A
- RNXT N/A
- Revenue
- PNF N/A
- RNXT $240,000.00
- Revenue This Year
- PNF N/A
- RNXT $3,186.05
- Revenue Next Year
- PNF N/A
- RNXT $291.93
- P/E Ratio
- PNF N/A
- RNXT N/A
- Revenue Growth
- PNF N/A
- RNXT N/A
- 52 Week Low
- PNF $6.37
- RNXT $0.75
- 52 Week High
- PNF $9.06
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- PNF 47.36
- RNXT 60.28
- Support Level
- PNF $6.89
- RNXT $1.31
- Resistance Level
- PNF $7.02
- RNXT $1.42
- Average True Range (ATR)
- PNF 0.07
- RNXT 0.06
- MACD
- PNF 0.01
- RNXT -0.01
- Stochastic Oscillator
- PNF 52.24
- RNXT 75.00
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.